dystrophic epidermolysis bullosa
Krystal Biotech secures FDA approval for redosable topical gene therapy
May 22, 2023Medical Communications FDA, Krystal Biotech, Paediatrics, dystrophic epidermolysis bullosa, gene therapy
US-based biotech company Krystal Biotech has announced that the US Food and Drug Administration (FDA) has approved its topical gene …
Latest content
October 28, 2026
Acumetis CEO Herspiegel steps down as Burden assumes role
October 27, 2026
